Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis Published: 15 Oct, 2021 | Tags: Bristol Myers Squibb, Zeposia, ozanimod, […]readmore
Tags : Verzenio
Shots: The P-III monarchE trial assessed Verzenio (150mg, bid) + SOC vs SOC alone in patients with EBC in a ratio (1:1) for 2yrs. Patients in both treatment arms were […]readmore
Shots: The approval of Verzenio is based on results of two P-III and one P-II study. The P-III MONARCH 3 study assessing Verzenio + anastrozole/letrozole vs PBO in 493 postmenopausal […]readmore
Shots: The P-III MONARCH 2 study involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 pre/peri- and postmenopausal women in a ratio (2:1) with HR+, HER2- metastatic […]readmore